plerixafor has been researched along with Lymphoma in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.82) | 29.6817 |
| 2010's | 48 (87.27) | 24.3611 |
| 2020's | 6 (10.91) | 2.80 |
| Authors | Studies |
|---|---|
| Brunn, A; Deckert, M; Montesinos-Rongen, M; Sanchez-Ruiz, M; Siebert, R; Siebert, S; Winter, C | 1 |
| Bosman, P; Boumendil, A; Celanovic, M; Chabannon, C; Dabrowska-Iwanicka, A; Dreger, P; Esquirol, A; Janikova, A; Jantunen, E; Liu, Q; Masszi, T; Montoto, S; Pohlreich, D; Russell, N; Sakellari, I; Scheid, C; Sureda, A; Thieblemont, C; Touzeau, C; van der Werf, S; Wahlin, BE | 1 |
| Alvarado-Navarro, DM; Cantú-Rodríguez, OG; Colunga-Pedraza, PR; Del Carmen Tarín-Arzaga, L; Flores-Jiménez, JA; Gómez-Almaguer, D; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; León, AG; Mejía-Jaramillo, G; Palomares-Leal, A; Salazar-Riojas, R; Sotomayor-Duque, G | 1 |
| Ali, S; Babae, N; Glerum, PJ; Herberts, C; Herold, R; Josephson, F; Karres, D; Papadouli, I; Pignatti, F; Straus, S; Thole, G; van Hennik, PB | 1 |
| Avalon, M; Bijou, F; Brunet de la Grange, P; Cabantous, T; Debeissat, C; Duchez, P; Ivanovic, Z; Mombled, M; Pasquet, JM; Pérard, B; Rodriguez, L; Sawai, KM; Thévenot, F; Vlaski-Lafarge, M | 1 |
| Araki, Y; Furuta, Y; Komatsu, N; Miyake, K; Nakamura, Y; Noguchi, M; Ohsaka, A; Okubo, M; Osawa, T; Sawada, T; Sekiguchi, Y; Tada, N; Yamatoya, K | 1 |
| Abu-Arja, R; Bhunia, N; Dalal, JD; Goyal, RK; Kang, HJ; Lee, AC; Loeb, DM; Mehyar, LS; O'Brien, TA; Ozkaynak, MF; Rangarajan, HG; Roberts, CH; Shaw, PJ; Shenoy, SS; Stanek, JR; Stein, J; Strahlendorf, C | 1 |
| Gawroński, K; Rzepecki, P; Sawicki, W; Wajs, J | 1 |
| Bosse, R; Duyster, J; Engelhardt, M; Greil, C; Hildenbeutel, S; Ihorst, G; Kiote-Schmidt, C; Kühbach, K; Wäsch, R | 1 |
| Culligan, DJ; Dong, B; Hay, AE; Lawrie, A; Robinson, N | 1 |
| Kogut, N; Krishnan, A; Nademanee, A; Shayani, S; Wang, S; Yuan, S | 1 |
| Abdel-Rahman, F; Al Rawi, O; Hussein, A; Hussein, N; Jazar, HA; Saad, A; Sharma, S; Tuffaha, HW | 1 |
| Bosi, A; Cascavilla, N; Guggiari, E; Imola, M; Lanza, F; Laszlo, D; Lemoli, RM; Martinelli, G; Martino, M; Milone, G; Olivieri, A; Pasini, A; Pavone, V; Rambaldi, A; Scortechini, I; Specchia, G; Todisco, E | 1 |
| Kořístek, Z; Lysák, D; Tichopád, A; Vítová, V | 1 |
| Nademanee, A; Salhotra, A; Wang, S; Yuan, S | 1 |
| Cupri, A; Di Marco, A; Di Martina, V; Leotta, S; Martino, M; Milone, G; Scalzulli, P; Schinocca, E; Spadaro, A; Spina, E; Tripepi, G | 1 |
| Carlo-Stella, C; Corradini, P; Farina, L; Guidetti, A; Longoni, P; Ravagnani, F; Roncari, L; Spina, F | 1 |
| Andritsos, LA; Devine, SM; Haverkos, BM; Jaglowski, SM; McBride, A; O'Donnell, L; Penza, S; Scholl, D; Vasu, S; Whittaker, B | 1 |
| Came, N; Demosthenous, L; Harrison, S; Herbert, KE; Link, E; Prince, HM; Ritchie, DS; Seymour, JF; Westerman, DA; Wiesner, G | 1 |
| Budisavljevic, MN; Butcher, C; Chhabra, S; Costa, LJ; Edwards, KH; Kang, Y; Kramer, C; Littleton, A; Schade, H; Schneider, M; Stuart, RK | 1 |
| Jang, JH; Jung, CW; Jung, SK; Kang, ES; Kim, DW; Kim, K; Kim, SJ; Kim, WS; Lee, KH | 1 |
| Barba, P; Duarte, RF; Encuentra, M; Esquirol, A; Garcia-Cerecedo, T; Grifols, JR; Martí, JM; Ortega, S; Pujol-Balaguer, MM; Pujol-Bosch, M; Querol, S; Sánchez-Ortega, I; Sanchez-Villegas, JM; Sancho, JM; Serra, A; Sierra, J | 1 |
| André, M; Baily, L; Dierickx, D; Huyngh, P; Lambert, C; Noens, L; Selleslag, D; Van de Velde, A; Willems, E; Zachee, P | 1 |
| Bell, J; Braithwaite, B; Callaghan, T; Clark, JO; Clark, RE; Francis, S; McGinnity, N; Salim, R; Vithanarachchi, U | 1 |
| Flowers, C; Gaylor, C; Harvey, RD; Jagirdar, N; Kaufman, J; Langston, A; Lechowicz, MJ; Lipscomb, C; Lonial, S; Nooka, A; Waller, EK | 1 |
| Bell, J; Braithwaite, B; Clark, JO; Clark, RE; Haycox, A; Houten, R; Martin, AP; McLeod, C; Richards, S | 1 |
| Craig, M; Cumpston, A; Hamadani, M; Kanate, AS; Leadmon, S; Luo, J; Shillingburg, A; Veltri, L; Watkins, K; Wen, S | 1 |
| Engert, A; Hartmann, T; Hübel, K; Monsef, I; Skoetz, N | 1 |
| Cho, SG; Do, YR; Eom, HS; Kim, H; Kim, JS; Kim, WS; Kwak, JY; Lee, J; Lee, JJ; Min, CK; Moon, JH; Park, S; Suh, C; Yang, DH; Yoon, DH; Yoon, SS | 1 |
| Baker, J; Cooper, DL; Foss, F; Medoff, E; Patel, N; Perreault, S; Pratt, K; Seropian, SE; Wu, Y | 1 |
| Duarte, R; Marín, P; Medina, L; Querol, S; Sancho, JM; Sureda, A | 1 |
| Jantunen, E; Mäntymaa, P; Nousiainen, T; Partanen, A; Pyörälä, M; Valtola, J; Varmavuo, V | 1 |
| Achtereekte, H; de la Rubia, J; Delgado, J; Douglas, KW; Duarte, RF; Gandhi, PJ; Gayoso, J; Goterriz, R; Kottaridis, P; Marín, P; Martínez-Chamorro, C; Mateos-Mazón, JJ; Morante, C; Ortiz, M; Ramírez, C; Russell, NH; Shaw, BE | 1 |
| Alexander, ET; Costa, LJ; Fouts, TV; Hogan, KR; Schaub, C; Stuart, RK | 1 |
| Agis, H; Baccarani, M; Casadei, B; Curti, A; D'Addio, A; Dan, E; Douglas, K; Giudice, V; Kopetzky, G; Lemoli, RM; Motta, MR; Rizzi, S; Soutar, R; Taioli, S; Worel, N | 1 |
| Greinix, HT; Kalhs, P; Kasparu, H; Linkesch, W; Nachbaur, D; Namberger, K; Neumeister, P; Rosskopf, K; Russ, G; Schloegl, E; Witt, V; Worel, N; Zojer, N | 1 |
| Jantunen, E; Kuittinen, T; Mahlamäki, E; Mäntymaa, P; Nousiainen, T; Pyörälä, M | 1 |
| Arakawa, F; Ohshima, K; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M | 1 |
| Alamos, SM; Antoniazzi, F; Arcaini, L; Balzarotti, M; Bonfichi, M; Farina, L; Guggiari, E; Laszlo, D; Martinelli, G; Morra, E; Rizzi, S; Rossi, G; Todisco, E; Zilioli, VR | 1 |
| Worel, N | 1 |
| Anderson, D; Flowers, CR; Gleason, C; Graiser, M; Hamilton, E; Kaufman, JL; Langston, A; Lechowicz, MJ; Li, J; Lonial, S; Prichard, JM; Renfroe, H; Vaughn, L; Waller, EK | 1 |
| Baker, J; Conkling-Walsh, A; Cooper, DL; Foss, F; Medoff, E; Pratt, K; Seropian, SE; Snyder, E; Yen, W | 1 |
| Fogle, R; Gale, M; Garron, C; Hu, Y; Jacques, G; Kaplan, J; Nguyen, TH; Shields, J; Siders, W; Swistak, M | 1 |
| Attolico, I; Coluzzi, S; Crescimanno, A; Di Nardo, E; Iacopino, P; Martino, M; Milone, G; Musso, M; Nuccorini, R; Olivieri, A; Ostuni, A; Pascale, S; Pavone, V; Rossini, B; Tedeschi, P | 1 |
| Jantunen, E | 1 |
| Keating, GM | 1 |
| Andreola, G; Babic, A; Laszlo, D; Martinelli, G; Negri, M; Rabascio, C | 1 |
| DiPersio, JF | 1 |
| Bensinger, WI; Gopal, AK; Holmberg, L; Karami, M; Linenberger, M; Macebeo, M; Mayor, J | 1 |
| Butcher, CD; Costa, LJ; Hogan, KR; Kang, Y; Kramer, C; Littleton, AL; Shoptaw, KB; Stuart, RK | 1 |
| Bains, T; Bubalo, J; Chen, AI; Fowler, C; Knight, R; Maziarz, RT; Murray, S; Shoop, K; Slater, S | 1 |
| Akı, SZ; Altuntaş, F; Ayyıldız, E; Baysal, NA; Dönmez, A; Ilhan, O; Sarı, I; Sıvgın, S; Tekgündüz, E; Tombuloğlu, M; Topçuoğlu, P; Unal, A; Yıldırım, R; Yüksel, MK | 1 |
| Calandra, GB; Flowers, CR; Hewes, LB; Kaufman, JL; Khoury, HJ; Langston, AA; Lechowicz, MJ; Lonial, S; Rados, KD; Vose, JM; Waller, EK | 1 |
| Calandra, G; DiPersio, J; Flomenberg, N | 1 |
6 review(s) available for plerixafor and Lymphoma
| Article | Year |
|---|---|
EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
Topics: Adult; Benzylamines; Child; Cyclams; Europe; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Transplantation, Autologous | 2020 |
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Topics: Benzylamines; Cyclams; Early Termination of Clinical Trials; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Time Factors; Transplantation, Autologous | 2015 |
CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target.
Topics: Benzylamines; Brain Neoplasms; Cell Movement; Chemokine CXCL12; Cyclams; Glioblastoma; Heterocyclic Compounds; Humans; Lymphoma; Neoplasm Metastasis; Protein Binding; Receptors, CXCR4; Signal Transduction; Stem Cells | 2011 |
Novel strategies for blood stem cell mobilization: special focus on plerixafor.
Topics: Animals; Anti-HIV Agents; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia; Lymphoma; Multiple Myeloma; Stem Cell Transplantation | 2011 |
Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
Topics: Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma | 2011 |
Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.
Topics: Anti-HIV Agents; Benzylamines; Bone Marrow; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Clinical Trials as Topic; Cyclams; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Protein Binding; Receptors, CXCR4; Recombinant Proteins; Transplantation, Autologous | 2005 |
11 trial(s) available for plerixafor and Lymphoma
| Article | Year |
|---|---|
Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Proof of Concept Study; Transplantation, Autologous | 2019 |
An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.
Topics: Adult; Aged; Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation | 2014 |
Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Topics: Adult; Anti-HIV Agents; Autografts; Benzylamines; Blood Component Removal; Cyclams; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins | 2014 |
Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor.
Topics: Aged; Anti-HIV Agents; Antigens, CD34; Autografts; Benzylamines; Blood Component Removal; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies | 2014 |
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Autografts; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Risk Factors | 2015 |
Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients.
Topics: Adult; Aged; Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukapheresis; Lymphoma; Male; Middle Aged; Multiple Myeloma | 2014 |
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cyclophosphamide; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Vincristine | 2015 |
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experienc
Topics: Adolescent; Adult; Aged; Antigens, CD34; Austria; Benzylamines; Combined Modality Therapy; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunoglobulin G; Leukapheresis; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Transplantation, Autologous; Young Adult | 2011 |
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Combined Modality Therapy; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Treatment Outcome; Young Adult | 2011 |
Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recovery of Function; Transplantation, Autologous | 2012 |
Plerixafor use in patients with previous mobilization failure: A multicenter experience.
Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2012 |
38 other study(ies) available for plerixafor and Lymphoma
| Article | Year |
|---|---|
AMD3100-Mediated CXCR4 Inhibition Impairs Development of Primary Lymphoma of the Central Nervous System.
Topics: Animals; Benzylamines; Brain; Chemokine CXCL12; Lymphoma; Mice; Receptors, CXCR4; Signal Transduction | 2023 |
Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor.
Topics: Benzylamines; Bone Marrow; Cyclams; Europe; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Neoplasm Recurrence, Local; Registries | 2020 |
Characteristics of cells with engraftment capacity within CD34+ cell population upon G-CSF and Plerixafor mobilization.
Topics: Animals; Antigens, CD34; Benzylamines; Child; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Mice; Middle Aged; Multiple Myeloma; Stem Cells | 2020 |
Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hospitals, University; Humans; Japan; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cells; Transplantation, Autologous | 2021 |
A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders.
Topics: Adolescent; Antigens, CD34; Benzylamines; Blood Component Removal; Child; Child, Preschool; Cohort Studies; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Humans; Infant; Lymphoma; Male; Medulloblastoma; Neoplasms; Neuroblastoma; Peripheral Blood Stem Cells; Retrospective Studies; Sarcoma; Young Adult | 2021 |
Mobilization of Hematopoietic Stem Cells for Hematopoietic Cells Autologous Transplantation with Use of Plerixafor.
Topics: Antigens, CD34; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Male; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome | 2017 |
Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
Topics: Benzylamines; Cell Count; Cost-Benefit Analysis; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Treatment Outcome | 2018 |
A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.
Topics: Antigens, CD34; Benzylamines; Blood Component Removal; Body Weight; Cost-Benefit Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Regression Analysis; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2013 |
Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent.
Topics: Adult; Aged; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Salvage Therapy | 2013 |
GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: collection effectiveness and cost effectiveness analysis.
Topics: Adult; Benzylamines; Cost-Benefit Analysis; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Retrospective Studies; Young Adult | 2014 |
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.
Topics: Adolescent; Adult; Aged; Benzylamines; Blood Component Removal; Chemoradiotherapy; Cyclams; Data Collection; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Italy; Leukapheresis; Lymphoma; Male; Middle Aged; Multiple Myeloma; Platelet Count; Predictive Value of Tests; Prospective Studies; Receptors, CXCR4; Young Adult | 2014 |
Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
Topics: Adolescent; Adult; Aged; Benzylamines; Child; Child, Preschool; Cost-Benefit Analysis; Cyclams; Cytapheresis; Czechoslovakia; Decision Trees; Female; Granulocyte Colony-Stimulating Factor; Health Expenditures; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Infant; Length of Stay; Lymphoma; Male; Middle Aged; Models, Economic; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Treatment Outcome; Young Adult | 2013 |
Plerixafor to the rescue: boosting peripheral blood stem cell mobilization in patients previously treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine (Hyper-CVAD) chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Treatment Outcome; Vincristine | 2014 |
Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Retrospective Studies; Young Adult | 2014 |
Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.
Topics: Adult; Aged; Algorithms; Antigens, CD34; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2014 |
Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Incidence; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Transplantation, Autologous | 2014 |
Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium.
Topics: Adult; Aged; Belgium; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prospective Studies; Transplantation, Autologous | 2015 |
Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.
Topics: Benzylamines; Cost-Benefit Analysis; Costs and Cost Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Historically Controlled Study; Humans; Lymphoma; Multiple Myeloma | 2016 |
Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cost-Benefit Analysis; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Young Adult | 2015 |
Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicent
Topics: Adult; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Prognosis; Republic of Korea; Retrospective Studies; Treatment Failure; Young Adult | 2016 |
Autologous Stem Cell Mobilization in the Age of Plerixafor.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Workflow | 2016 |
[Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Transplantation, Autologous | 2016 |
Pre-emptive plerixafor injection in lymphoma patients mobilized with chemotherapy plus pegfilgrastim followed by apheresis on the same day.
Topics: Adult; Aged; Benzylamines; Blood Component Removal; Cyclams; Female; Filgrastim; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Polyethylene Glycols; Premedication; Time Factors | 2017 |
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cohort Studies; Compassionate Use Trials; Cyclams; Drug Therapy, Combination; European Union; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2011 |
Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
Topics: Algorithms; Antigens, CD34; Benzylamines; Blood Cell Count; Blood Component Removal; Cohort Studies; Cost Savings; Cyclams; Decision Support Techniques; Drug Therapy, Combination; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2011 |
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Transplantation, Autologous | 2011 |
Plerixafor. Only for certain patients when G-CSF stem cell mobilisation fails.
Topics: Benzylamines; Clinical Trials as Topic; Cyclams; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Receptors, CXCR4 | 2010 |
Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Receptors, CXCR4; Recombinant Proteins; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2011 |
Plerixafor--the magic bullet in stem cell mobilization failure?
Topics: Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Peripheral Blood Stem Cell Transplantation | 2011 |
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cohort Studies; Cost-Benefit Analysis; Cyclams; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation, Autologous; Young Adult | 2011 |
Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cell Count; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2011 |
Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Chemotaxis; Cyclams; Drug Synergism; Flow Cytometry; Heterocyclic Compounds; Humans; Lymphoma; Mice; Mice, SCID; Phosphorylation; Pyridines; Receptors, CXCR4; Rituximab; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow Transplantation; Combined Modality Therapy; Cyclams; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Transplantation, Autologous; Treatment Outcome; Young Adult | 2012 |
New hope for mobilization failures . . . again.
Topics: Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation | 2012 |
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzylamines; Blood Component Removal; Cyclams; Cyclophosphamide; Dexamethasone; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kinetics; Lymphoma; Middle Aged; Multiple Myeloma | 2012 |
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Blood Component Removal; Cost-Benefit Analysis; Cyclams; Drug Costs; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2012 |
Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization.
Topics: Adult; Aged; Algorithms; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Paraproteinemias; Transplantation, Autologous; Treatment Outcome | 2012 |
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Lymphoma; Rituximab; Stem Cell Transplantation | 2013 |